Shield Therapeutics plc (AIM:STX)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 62.61M +140.4% |
| Revenue (ttm) | 36.93M +54.4% |
| Net Income | -13.12M |
| EPS | -0.01 |
| Shares Out | 1.07B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,085,069 |
| Open | 5.77 |
| Previous Close | 5.86 |
| Day's Range | 5.70 - 6.00 |
| 52-Week Range | 2.25 - 12.50 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 17.33 (+193.73%) |
| Earnings Date | Jun 4, 2026 |
About Shield Therapeutics
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom. [Read more]
Full Company ProfileFinancial Performance
In 2025, Shield Therapeutics's revenue was $49.70 million, an increase of 54.45% compared to the previous year's $32.18 million. Losses were -$17.66 million, -35.05% less than in 2024.
Financial numbers in USD Financial StatementsNews
Shield Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw $18.4M in revenue, 44% prescription growth, and EBIT profitability, aided by a $7.9M China milestone. U.S. commercial sales drive growth, while Medicaid faces new prior authorization hurdles. Focus remains on expanding Accrufer, global markets, and acquiring a second product.
Shield Therapeutics Earnings release: Q1 2026
Shield Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Shield Therapeutics Earnings release: Trading update
Shield Therapeutics released its earnings on May 1, 2026, summarizing the period's financial results.
Shield Therapeutics Annual report: H2 2025
Shield Therapeutics has published its H2 2025 annual report on April 9, 2026.
Shield Therapeutics Earnings Call Transcript: Q4 2025
Cash flow positive in Q4 2025, with $50M in annual revenue and 56% U.S. growth. ACCRUFeR leads the U.S. market, with international expansion and new pediatric indications underway. Profitability and further portfolio diversification targeted for 2026.
Shield Therapeutics Earnings release: Q4 2025
Shield Therapeutics released its Q4 2025 earnings on January 22, 2026, summarizing the period's financial results.
Shield Therapeutics Slides: Q4 2025
Shield Therapeutics has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 22, 2026.
Shield Therapeutics Transcript: Trading Update
Q3 2025 saw strong revenue and prescription growth for Accrufer, with robust digital and sales force strategies driving market expansion. Cash flow positivity is expected by Q4 2025, and ex-U.S. growth continues with new launches and regulatory progress. Influencer marketing and targeted outreach are delivering measurable results.
Shield Therapeutics Earnings release: Trading Update
Shield Therapeutics released its earnings on October 23, 2025, summarizing the period's financial results.
Shield Therapeutics Quarterly report: H1 2025
Shield Therapeutics has published its H1 2025 quarterly earnings report on September 3, 2025.
Shield Therapeutics Transcript: Trading Update
ACCRUFeR saw record Q2 growth, doubling net revenues to $12.8 million and achieving 47,000 prescriptions, driven by expanded digital marketing and optimized sales force. Global partnerships and pediatric expansion support continued momentum, with cash flow positivity targeted by end-2025.
Shield Therapeutics Earnings release: Trading Update
Shield Therapeutics released its earnings on July 23, 2025, summarizing the period's financial results.
OTC Markets Group Welcomes Shield Therapeutics PLC to OTCQX
NEW YORK, May 17, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Shield Therapeutics PLC (LSE: STXS; OT...